Literature DB >> 8411290

Prophylactic vena cava filter insertion in severely injured trauma patients: indications and preliminary results.

F B Rogers1, S R Shackford, J Wilson, M A Ricci, C S Morris.   

Abstract

Pulmonary embolism (PE) remains a significant problem in trauma patients. A 5-year review at this institution revealed 25 PEs (seven fatal) in 2525 admitted trauma patients (1% incidence). Three groups of high-risk patients were identified: (1) those with severe head injury and coma; (2) those with spinal cord injuries with neurologic deficit; and (3) those with pelvic and long bone fractures. The relative risk of PE in these high-risk patients was 21 to 54 times that of the general trauma population. Beginning in July 1991, as prophylaxis against PE, vena cava filters (VCF) were inserted in patients whose injuries placed them in a high-risk group. Thirty-four patients had VCFs inserted percutaneously in the radiology suite without complications. On follow-up examination, 17.6% developed documented lower extremity deep vein thrombosis. There were no PEs. Overall, the incidence of PE in the general trauma population was significantly decreased from 1% to 0.25% (p < 0.05; chi 2). We conclude that insertion of VCFs in high-risk trauma patients is safe and efficacious in decreasing the incidence of PE.

Entities:  

Mesh:

Year:  1993        PMID: 8411290     DOI: 10.1097/00005373-199310000-00021

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  17 in total

1.  Inferior vena cava filtration in the management of venous thromboembolism: filtering the data.

Authors:  Christopher Molvar
Journal:  Semin Intervent Radiol       Date:  2012-09       Impact factor: 1.513

2.  Research priorities in neurocritical care.

Authors:  R G Geocadin; T P Bleck; W J Koroshetz; C S Robertson; O O Zaidat; P D LeRoux; C A C Wijman; J I Suarez
Journal:  Neurocrit Care       Date:  2012-02       Impact factor: 3.210

3.  Thromboprophylaxis for trauma patients.

Authors:  Luis Manuel Barrera Lozano; Pablo Perel; Katharine Ker; Roberto Cirocchi; Eriberto Farinella; Carlos Hernando Morales
Journal:  Cochrane Database Syst Rev       Date:  2010

4.  The use of retrievable inferior vena cava filters in the trauma population.

Authors:  Kristina Spate; Faisal Aziz; Bauer E Sumpio
Journal:  Int J Angiol       Date:  2008

5.  Elective bedside surgery in critically injured patients is safe and cost-effective.

Authors:  T L Van Natta; J A Morris; V A Eddy; C R Nunn; E J Rutherford; D Neuzil; J M Jenkins; J G Bass
Journal:  Ann Surg       Date:  1998-05       Impact factor: 12.969

Review 6.  Pulmonary embolism prophylaxis with inferior vena cava filters in trauma patients: a systematic review using the meta-analysis of observational studies in epidemiology (MOOSE) guidelines.

Authors:  Anita Rajasekhar; Richard Lottenberg; Lawrence Lottenberg; Huazhi Liu; Darwin Ang
Journal:  J Thromb Thrombolysis       Date:  2011-07       Impact factor: 2.300

Review 7.  A growing problem: implications of obesity on the provision of trauma care.

Authors:  Ahmed Twaij; Mikael H Sodergren; Philip H Pucher; Nicola Batrick; Sanjay Purkayastha
Journal:  Obes Surg       Date:  2013-12       Impact factor: 4.129

8.  Complications related to deep venous thrombosis prophylaxis in trauma: a systematic review of the literature.

Authors:  Indraneel Datta; Chad G Ball; Lucas Rudmik; S Morad Hameed; John B Kortbeek
Journal:  J Trauma Manag Outcomes       Date:  2010-01-06

9.  Prophylactic anticoagulation to prevent venous thromboembolism in traumatic intracranial hemorrhage: a decision analysis.

Authors:  Damon C Scales; Jay Riva-Cambrin; Dave Wells; Valerie Athaide; John T Granton; Allan S Detsky
Journal:  Crit Care       Date:  2010-04-20       Impact factor: 9.097

10.  Bedside placement of removable vena cava filters guided by intravascular ultrasound in the critically injured.

Authors:  Konstantinos Spaniolas; George C Velmahos; Christopher Kwolek; Alice Gervasini; Marc De Moya; Hasan B Alam
Journal:  World J Surg       Date:  2008-07       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.